Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Piattaforma di telemonitoraggio "CUREETY TECHCARE" rispetto allo standard di cura per i pazienti mTBNC che iniziano un trattamento di prima linea (ALTERNATIVE)

24 settembre 2026 aggiornato da: UNICANCER

Uno studio randomizzato di fase III che confronta la piattaforma di telemonitoraggio digitale "CUREETY TECHCARE" con gli standard di cura abituali in pazienti con carcinoma mammario metastatico triplo negativo che iniziano un trattamento sistemico di prima linea

The goal of this clinical trial is to assess whether adding telemonitoring (the digital telemonitoring platform "CUREETY TECHCARE"), to standard care, will benefit patients with previously untreated metastatic triple-negative breast cancer starting first-line cancer therapy.

The main questions it aims to answer are:

  • Is patient quality of life improved by using the telemonitoring platform?
  • Are patients hospitalized less frequently when using the telemonitoring platform?
  • Is the patient overall survival improved by telemonitoring ?

Researchers will compare data from patients using telemonitoring while receiving standard care with data from patients receiving only standard care.

Participants using telemonitoring will answer questions about their symptoms on the platform. The platform will analyze these symptoms, assess the patient's general condition and provide advice accordingly. Medical staff will also access the platform to monitor the patient's general condition and contact them if necessary.

Panoramica dello studio

Stato

Terminato

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Effettivo)

31

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Arras, Francia
        • Institut de Cancérologie des Hauts-de-France (ICHF)
      • Auxerre, Francia
        • Centre Hospitalier d'Auxerre
      • Avignon, Francia
        • Sainte Catherine - Institut du Cancer Avignon Provence
      • Bayeux, Francia
        • CH Aunay-Bayeux
      • Beauvais, Francia
        • Centre Hospitalier Simone Veil de Beauvais
      • Beuvry, Francia
        • ICHF - Centre Pierre Curie
      • Blois, Francia
        • Hôpital Simone Veil de Blois
      • Bordeaux, Francia
        • Polyclinique bordeaux nord
      • Bourg-en-Bresse, Francia
        • Centre Hospitalier Fleyriat
      • Caen, Francia
        • Centre de Cancérologie Privé de Caen Maurice Tubiana
      • Caen, Francia
        • Centre Francois Baclesse
      • Carcassonne, Francia
        • Centre hospitalier de Carcasonne
      • Chambray-lès-Tours, Francia
        • Recherche Oncologie Clinqiue 37 (ROC 37)
      • Cholet, Francia
        • CH de Cholet
      • Colmar, Francia
        • CH Colmar
      • Creil, Francia
        • Groupe Hospitalier Public du Sud de l'Oise (GHPSO)
      • Dijon, Francia
        • Centre Georges François Leclerc
      • Dunkirk, Francia
        • Institut Andrée Dutreix
      • Fréjus, Francia
        • Centre Hospitalier Intercommunal de Fréjus Saint Raphael
      • Grenoble, Francia
        • Groupe Hospitalier Mutualiste de Grenoble
      • La Rochelle, Francia
        • Groupe Hospitalier de La Rochelle-Ré-Aunis
      • La Réunion, Francia
        • CHU de la réunion
      • La Réunion, Francia
        • Clinique Sainte Clotilde
      • La Tronche, Francia
        • CHU Grenoble Alpes
      • Le Coudray, Francia
        • Centre Hospitalier Louis Pasteur
      • Le Mans, Francia
        • Centre Hospitalier Le Mans
      • Le Puy-en-Velay, Francia
        • Centre Hospitalier Emile Roux
      • Lorient, Francia
        • GHBS Lorient
      • Lyon, Francia
        • Clinique de la Sauvegarde
      • Lyon, Francia
        • Centre Leon Berard
      • Lyon, Francia
        • Hôpital Privé Jean Mermoz
      • Marseille, Francia
        • Institut Paoli Calmettes
      • Mont-de-Marsan, Francia
        • CHI de Mont-de-Marsan et du Pays des Sources
      • Montpellier, Francia
        • Centre de Cancérologie du Grand Montpellier
      • Nantes, Francia
        • Hôpital Privé du Confluent
      • Neuilly-sur-Seine, Francia
        • Clinique Ambroise-Pare Hartmann
      • Neuilly-sur-Seine, Francia
        • Hôpital Américain de PARIS
      • Nîmes, Francia
        • CHU de Nimes
      • Orléans, Francia
        • CHR Orleans
      • Osny, Francia
        • CHP Sainte-Marie
      • Paris, Francia
        • Diaconesses Croix Saint-Simon Hospital Complex
      • Pau, Francia
        • Centre hospitalier de Pau
      • Plérin, Francia
        • CARIO - Hopital Privé des Cotes d'Armor
      • Poitiers, Francia
        • CHU de Poitiers
      • Reims, Francia
        • Institut Godinot
      • Rouen, Francia
        • Clinique Mathilde - Les Hôpitaux Privés Rouennais
      • Saint-Etienne, Francia
        • CHU de Saint-Etienne
      • Saint-Mandé, Francia
        • Hia Begin
      • Tours, Francia
        • CHU de Tours
      • Vandœuvre-lès-Nancy, Francia
        • Institut de Cancérologie de Lorraine
      • Épagny, Francia
        • CH Annecy Genevois

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Signed a written informed consent form prior to participate in the study. Note: In case of physical incapacitation, a trusted representative of their choice, which is not the Investigator or sponsor, can sign on the behalf of the patients
  • Patients ≥18 years of age.
  • Patient with histologically documented metastatic triple negative breast cancer (ER (Oestrogen receptor) and PR (Progesterone receptor) <10%, Her2 negative status).
  • Life expectancy > 6 months as per investigator estimate.
  • Patient initiating a marketed authorized first-line systemic treatment in the metastatic setting.
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2.
  • Patient having completed the EORTC QLQ-C30 and EORTC QLQ-BR45 at baseline (response to questions 29 and 30 of EORTC QLQ-C30 at baseline are mandatory)
  • Affiliated to the social security system or equivalent health insurance.
  • Patient able and willing to complete web-based self-reported questionnaires, from initiation of first-line treatment and for the duration of the study (over multiple treatment lines)
  • Patient has access to a computer, tablet, or smartphone connected to the Internet.

Exclusion Criteria:

  • Participation in another clinical trial using telemonitoring.
  • Physical or psychological incapacity of the patient to use the digital telemonitoring Cureety Techcare, according to the investigator's discretion.
  • Patient deprived of their liberty or under protective custody or guardianship.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Terapia di supporto
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Nessun intervento: Gruppo standard di cura
Sperimentale: Telemonitoring group

Standard of care with digital telemonitoring "Cureety TechCare". The telemonitoring will comprise weekly adverse event (AE) evaluations and their analyses by the "Cureety TechCare".

Each week, patients complete a questionnaire via the Cureety platform, specifically designed for the drug class or specific treatment being administered. Based on their responses, the Cureety TechCare algorithm classifies patients into one of four risk categories: "correct" (green), "compromised" (yellow), "state to be monitored" (orange), or "critical state" (red). (Note: the color code is not visible to the patient).

The medical team uses the dashboard for daily patient monitoring and manages alerts related to the "clinical classification" of the patient's condition. The physician in charge of telemonitoring interprets the data, adjusts the treatment as needed, and provides supportive care during standard care consultations. Patients are also notified of alerts with tailored messages guiding them on the actions to take according to the category determined by the device.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Time to definitive Health-Related Quality of life score Deterioration
Lasso di tempo: At baseline then every 3 months, up to 24 months

The time to definitive Health-Related Quality of life score Deterioration is the length of time from randomization to the first deterioration of ≥ 10 points out of 100 or ≥2 points out of 14 in the global health status (GHS) score (items 29 and 30 of the QLQ-C30) compared with the baseline, assuming no improvement of at least 2 points in the GHS score compared with the baseline has occurred.

The responses to the items 29-30 of the QLQ-C30 will be scored using the QLQ scoring manual. These 2 items have possible values ranging from 1 (very bad) to 7 (excellent) corresponding to a sum from 2 to 14 points. After conversion to percentages, the GHS will range from 0% to 100%. The higher the value, the better the quality of life.

At baseline then every 3 months, up to 24 months
Hospitalization-free survival
Lasso di tempo: From randomization to death from any cause, up to 24 months

Hospitalization-free survival is the length of time from randomization during which patients enrolled in the study are not hospitalized and remain alive.

From randomization to death from any cause, up to 24 months
Overall survival
Lasso di tempo: From randomization to death from any cause, up to 24 months after last inclusion

overall survival is the length of time from randomization during which patients enrolled in the study remain alive.

From randomization to death from any cause, up to 24 months after last inclusion

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Time-to-treatment failure
Lasso di tempo: From randomization to treatment discontinuation, up to 24 months

Time-to-treatment failure is the time interval (in months) between the initiation of first-line chemotherapy and its premature discontinuation, irrespective of the reason for discontinuation.

From randomization to treatment discontinuation, up to 24 months
Toxicity-free survival
Lasso di tempo: From randomization until the first event, up to 24 months

The National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5) is widely accepted in the oncology research community as the leading rating scale for adverse events. This scale, divided into five grades (1 = "mild," 2 = "moderate," 3 = "severe," 4 = "life-threatening," and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders. Toxicity-free survival is defined as the time from randomization to the first event among a grade 3-4 non-hematological adverse event (graded using CTCAE version 5.0), a hospitalization for safety reasons, or death from any cause, whichever occurs first.

From randomization until the first event, up to 24 months
Time to clinical deterioration
Lasso di tempo: From randomization, to the date of the first clinical deterioration, up to 24 months

-Time to clinical deterioration is defined by the time between randomization and deterioration of patient's level of functioning determined by the Eastern Cooperative Oncology Group (ECOG) performance status scale. The ECOG, widely accepted in the community of oncology research to assess how the disease affects the daily living abilities of the patient, is composed of 5 levels from grade 0 (fully active, able to carry on all pre-disease performance without restriction) to grade 5 (dead).

From randomization, to the date of the first clinical deterioration, up to 24 months
Number of treatment lines
Lasso di tempo: Throughout study completion, up to 24 months

Number of successive treatment lines offered to the patient from randomization to the end of the study.

Throughout study completion, up to 24 months
Incidence of Adverse Events
Lasso di tempo: Throughout study completion, up to 24 months

The National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5) is widely accepted in the community of oncology research as the leading rating scale for adverse events. This scale, divided into 5 grades (1 = "mild", 2 = "moderate", 3 = "severe", 4 = "life-threatening", and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders.

Throughout study completion, up to 24 months
Quality of life questionnaire - Core 30 (QLQ-C30)
Lasso di tempo: At baseline then every 3 weeks, up to 24 months

Developed by the EORTC, this self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials.

The questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease.

All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

At baseline then every 3 weeks, up to 24 months
Quality of Life Questionnaire - Breast cancer module (QLQ-BR45)
Lasso di tempo: At baseline then every 3 weeks, up to 24 months

This EORTC breast cancer specific questionnaire is intended to supplement the QLQ-C30.

The QLQ-BR45 incorporates nine multi-item scales to assess body image, sexual functioning, breast satisfaction, systemic therapy side effects, arm symptoms, breast symptoms, endocrine therapy symptoms, skin mucosis symptoms, endocrine sexual symptoms. In addition, single items assess sexual enjoyment, future perspective and being upset by hair loss. All items are rated on a four-point Likert-type scale (1 = "not at all", 2 = "a little", 3 = "quite a bit", and 4 = "very much"), and are linearly transformed to a 0-100 scale. Higher scores indicate more severe symptoms or problems for all items.

At baseline then every 3 weeks, up to 24 months
Treatment compliance and extent of exposure
Lasso di tempo: Throughout study completion, up to 24 months

The treatment compliance and extent of exposure will be assess using dose intensity, treatment delays and dose reductions.

Throughout study completion, up to 24 months
Compliance with the use of Cureety digital telemonitoring
Lasso di tempo: Throughout study completion, up to 24 months

Compliance is measured by the frequency of patient responses to the Cureety telemonitoring questionnaires.

Throughout study completion, up to 24 months
Satisfaction with Cureety telemonitoring
Lasso di tempo: 3 months after randomisation for the patients and 1 year after the site activation for medical team

Satisfaction with Cureety telemonitoring is measured by the percentage of participants (patients and medical team [including nurse, clinical research associate, and investigators]) satisfied by the regular usage of the Cureety telemonitoring tool.

3 months after randomisation for the patients and 1 year after the site activation for medical team
Patient's global satisfaction with care using the data of the EORTC OUT-PATSAT-35
Lasso di tempo: 6 months after randomisation

The OUT-PATSAT35 is a 35-item satisfaction with care questionnaire measuring cancer outpatients' perception of hospital doctors and nurses, as well as aspects of care organisation and services. Each item is rated from 1 to 5 (bad to excellent).

6 months after randomisation
Socio-economic impact of digital telemonitoring
Lasso di tempo: Throughout study completion, up to 24 months after randomization

Socio-economic impact of digital telemonitoring will be assessed using the number of days of hospitalization and the number of unscheduled hospitalizations and emergency consultations

Throughout study completion, up to 24 months after randomization

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Jérôme MARTIN-BABAU, MD, Armorican Centre for Radiotherapy, Medical Imaging and Oncology, CARIO, Plérin
  • Investigatore principale: Florence JOLY, MD, François Baclesse Center, Caen
  • Investigatore principale: Frédéric FITENI, MD, University hospital of Nîmes

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

25 luglio 2024

Completamento primario (Effettivo)

1 dicembre 2025

Completamento dello studio (Effettivo)

12 dicembre 2025

Date di iscrizione allo studio

Primo inviato

10 luglio 2024

Primo inviato che soddisfa i criteri di controllo qualità

10 luglio 2024

Primo Inserito (Effettivo)

17 luglio 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

29 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

24 settembre 2026

Ultimo verificato

1 agosto 2025

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • UC-BCG-2309
  • IDRCB NUMBER: 2023-A02477-38 (Altro identificatore: CPP Sud-Méditerranée III)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual Participant Data will not be shared at an individual level. Those data will be part of the study database including all enrolled patients.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .